What is HC Wainwright's Estimate for Vericel Q4 Earnings?

Key Points

• HC Wainwright raised its Q4 2026 EPS estimate for Vericel to $0.62 from $0.50 and forecasts $0.53 EPS for Q4 2027. It maintained a Buy rating and a $75 price target.
• Vericel’s latest quarter beat expectations, with EPS of $0.27 versus $0.06 expected and revenue of $85.37 million versus $77.95 million; revenue rose 26.5% year over year.
• Analyst sentiment is broadly positive: MarketBeat reports a Moderate Buy consensus and an average price target of $60.80. Vericel also raised its 2026 revenue outlook to $344 million–$346 million.

Vericel Corporation (NASDAQ:VCEL - Free Report) - Stock analysts at HC Wainwright raised their Q4 2026 earnings per share (EPS) estimates for shares of Vericel in a note issued to investors on Friday, November 6th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of $0.62 for the quarter, up from their prior forecast of $0.50. HC Wainwright has a "Buy" rating and a $75.00 price objective on the stock. The consensus estimate for Vericel's current full-year earnings is $0.54 per share. HC Wainwright also issued estimates for Vericel's Q4 2027 earnings at $0.53 EPS.

A number of other equities analysts also recently commented on VCEL. Truist Financial set a $65.00 price objective on shares of Vericel in a report on Friday. Weiss Ratings reissued a "hold (c)" rating on shares of Vericel in a report on Thursday, October 29th. Wall Street Zen upgraded shares of Vericel from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Canaccord Genuity Group set a $60.00 price target on shares of Vericel in a report on Thursday, July 30th. Finally, TD Cowen lifted their price target on shares of Vericel from $55.00 to $58.00 and gave the company a "buy" rating in a report on Friday, July 31st. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $60.80.

Vericel Stock Performance

VCEL stock opened at $54.62 on Monday. The stock's 50 day simple moving average is $41.01 and its 200 day simple moving average is $38.90. Vericel has a 12-month low of $28.95 and a 12-month high of $55.60. The firm has a market cap of $2.80 billion, a P/E ratio of 85.35 and a beta of 1.08.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.06 by $0.21. Vericel had a return on equity of 9.09% and a net margin of 10.27%. The company had revenue of $85.37 million during the quarter, compared to analyst estimates of $77.95 million. During the same quarter last year, the firm earned $0.10 EPS. The business's revenue was up 26.5% on a year-over-year basis.

Insider Transactions at Vericel

In related news, insider Jonathan Siegal sold 1,500 shares of the business's stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $52.90, for a total transaction of $79,350.00. Following the completion of the transaction, the insider owned 1,259 shares in the company, valued at $66,601.10. The trade was a 54.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Sean C. Flynn sold 15,000 shares of the company's stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $51.92, for a total value of $778,800.00. Following the transaction, the insider owned 1,990 shares of the company's stock, valued at approximately $103,320.80. The trade was a 88.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 22,000 shares of company stock worth $1,128,340. 7.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Vericel

Several hedge funds and other institutional investors have recently modified their holdings of the company. Aberdeen Group plc boosted its stake in Vericel by 204.7% during the 3rd quarter. Aberdeen Group plc now owns 2,164,250 shares of the biotechnology company's stock valued at $86,873,000 after purchasing an additional 1,454,012 shares during the period. Allworth Financial LP grew its position in Vericel by 53.0% in the 3rd quarter. Allworth Financial LP now owns 2,052 shares of the biotechnology company's stock worth $91,000 after purchasing an additional 711 shares during the last quarter. Gagnon Securities LLC increased its stake in shares of Vericel by 7.3% in the third quarter. Gagnon Securities LLC now owns 7,839 shares of the biotechnology company's stock valued at $315,000 after purchasing an additional 536 shares during the period. Maryland State Retirement & Pension System increased its stake in shares of Vericel by 53.3% in the third quarter. Maryland State Retirement & Pension System now owns 11,395 shares of the biotechnology company's stock valued at $457,000 after purchasing an additional 3,963 shares during the period. Finally, Illinois Municipal Retirement Fund acquired a new stake in shares of Vericel in the third quarter valued at approximately $1,071,000.

More Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient's own cells or biologic materials to support tissue repair and healing.

Vericel's primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.